Vir Biotechnology (VIR) EBT (2018 - 2026)

Vir Biotechnology has disclosed EBT across 9 years of filings, most recently posting -$125.5 million for Q1 2026.

• EBT for Q1 2026 came in at -$125.5 million, down 3.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$442.3 million (up 23.61% YoY), and the FY2025 annual result was -$437.8 million, up 16.31% from the prior year.
• EBT came in at -$125.5 million for Q1 2026 at Vir Biotechnology, down from -$43.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $921.9 million in Q1 2022 to a low of -$233.7 million in Q2 2022.
• The 5-year median for EBT is -$125.5 million (2026), against an average of -$56.5 million.
• Peak annual rise in EBT reached 646.43% in 2022, while the deepest fall reached 477.79% in 2022.
• Vir Biotechnology's EBT stood at -$151.6 million in 2022, then advanced by 20.36% to -$120.8 million in 2023, then climbed by 13.32% to -$104.7 million in 2024, then soared by 58.86% to -$43.1 million in 2025, then sank by 191.51% to -$125.5 million in 2026.
• The last three EBT figures came in at -$125.5 million (Q1 2026), -$43.1 million (Q4 2025), and -$163.0 million (Q3 2025), per Business Quant data.